Cadre (CDRE) Competitors $32.97 +0.20 (+0.61%) Closing price 03:59 PM EasternExtended Trading$33.11 +0.14 (+0.42%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CDRE vs. SLNO, TMDX, NVST, LIVN, WRBY, INSP, LQDA, PRCT, LMAT, and AORTShould you be buying Cadre stock or one of its competitors? The main competitors of Cadre include Soleno Therapeutics (SLNO), TransMedics Group (TMDX), Envista (NVST), LivaNova (LIVN), Warby Parker (WRBY), Inspire Medical Systems (INSP), Liquidia Technologies (LQDA), PROCEPT BioRobotics (PRCT), LeMaitre Vascular (LMAT), and Artivion (AORT). These companies are all part of the "medical equipment" industry. Cadre vs. Its Competitors Soleno Therapeutics TransMedics Group Envista LivaNova Warby Parker Inspire Medical Systems Liquidia Technologies PROCEPT BioRobotics LeMaitre Vascular Artivion Cadre (NYSE:CDRE) and Soleno Therapeutics (NASDAQ:SLNO) are both medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings. Is CDRE or SLNO more profitable? Cadre has a net margin of 6.65% compared to Soleno Therapeutics' net margin of 0.00%. Cadre's return on equity of 12.08% beat Soleno Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cadre6.65% 12.08% 5.60% Soleno Therapeutics N/A -73.74%-56.67% Do insiders and institutionals hold more shares of CDRE or SLNO? 44.0% of Cadre shares are owned by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are owned by institutional investors. 31.5% of Cadre shares are owned by company insiders. Comparatively, 6.4% of Soleno Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better earnings & valuation, CDRE or SLNO? Cadre has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCadre$572.61M2.34$36.13M$0.9435.07Soleno TherapeuticsN/AN/A-$175.85M-$4.14-12.01 Which has more risk and volatility, CDRE or SLNO? Cadre has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -2.71, indicating that its stock price is 371% less volatile than the S&P 500. Does the media favor CDRE or SLNO? In the previous week, Soleno Therapeutics had 30 more articles in the media than Cadre. MarketBeat recorded 36 mentions for Soleno Therapeutics and 6 mentions for Cadre. Cadre's average media sentiment score of 1.24 beat Soleno Therapeutics' score of 0.57 indicating that Cadre is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cadre 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Soleno Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 13 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Positive Do analysts rate CDRE or SLNO? Cadre presently has a consensus target price of $31.50, suggesting a potential downside of 4.46%. Soleno Therapeutics has a consensus target price of $115.09, suggesting a potential upside of 131.52%. Given Soleno Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Soleno Therapeutics is more favorable than Cadre.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cadre 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08 SummaryCadre beats Soleno Therapeutics on 10 of the 16 factors compared between the two stocks. Get Cadre News Delivered to You Automatically Sign up to receive the latest news and ratings for CDRE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDRE vs. The Competition Export to ExcelMetricCadrePROTECTION IndustryIndustrials SectorNYSE ExchangeMarket Cap$1.34B$3.49B$7.83B$21.37BDividend Yield1.17%1.79%4.56%3.49%P/E Ratio35.0721.29309.7829.83Price / Sales2.345.61211.9588.56Price / Cash22.9680.8927.9018.13Price / Book4.3012.624.634.58Net Income$36.13M$109.95M$798.53M$998.53M7 Day Performance5.30%5.49%1.29%1.07%1 Month Performance13.49%7.86%1.72%4.41%1 Year Performance-8.70%41.59%27.34%14.45% Cadre Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDRECadre2.8317 of 5 stars$32.97+0.6%$31.50-4.5%-8.5%$1.34B$572.61M35.072,284Positive NewsAnalyst UpgradeHigh Trading VolumeSLNOSoleno Therapeutics4.4279 of 5 stars$72.30+3.6%$115.09+59.2%-3.2%$3.71BN/A-17.4630Short Interest ↑TMDXTransMedics Group2.4572 of 5 stars$105.58+1.5%$122.11+15.7%-24.5%$3.55B$441.54M54.70210Analyst ForecastNVSTEnvista3.8121 of 5 stars$21.14-0.8%$20.92-1.0%+8.8%$3.54B$2.51B66.0512,300Positive NewsLIVNLivaNova3.0804 of 5 stars$58.32+0.6%$59.71+2.4%+14.2%$3.17B$1.25B-14.992,900Positive NewsWRBYWarby Parker1.5103 of 5 stars$26.74+2.8%$24.06-10.0%+80.0%$2.74B$771.32M-382.003,780Positive NewsAnalyst UpgradeInsider TradeINSPInspire Medical Systems4.8955 of 5 stars$83.51-3.4%$164.50+97.0%-60.3%$2.56B$802.80M48.271,246Positive NewsLQDALiquidia Technologies3.7018 of 5 stars$27.98-3.0%$32.11+14.8%+173.3%$2.48B$14M-16.4650Positive NewsPRCTPROCEPT BioRobotics3.1451 of 5 stars$38.92-4.3%$73.22+88.1%-53.2%$2.26B$224.50M-25.11430Positive NewsAnalyst ForecastLMATLeMaitre Vascular3.1652 of 5 stars$97.07-0.4%$97.60+0.5%+3.0%$2.21B$219.86M47.12490Positive NewsAORTArtivion2.9028 of 5 stars$43.34-0.3%$40.63-6.2%+57.4%$2.05B$388.54M-103.191,600Positive News Related Companies and Tools Related Companies SLNO Alternatives TMDX Alternatives NVST Alternatives LIVN Alternatives WRBY Alternatives INSP Alternatives LQDA Alternatives PRCT Alternatives LMAT Alternatives AORT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CDRE) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadre Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadre With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CDRE Stock Alerts